![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
500kB |
| Item Type: | Letter |
|---|---|
| Title: | Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group |
| Creators Name: | Damaschin, C. and Goergen, H. and Kreissl, S. and Plütschow, A. and Breywisch, F. and Mathas, S. and Meissner, J. and Sökler, M. and Topp, M.S. and Vucinic, V. and Zimmermann, A. and von Tresckow, B. and Fuchs, M. and Engert, A. and Borchmann, P. and Eichenauer, D.A. |
| Keywords: | Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Brentuximab Vedotin, Cyclophosphamide, Etoposide, Follow-Up Studies, Hodgkin Disease, Local Neoplasm Recurrence, Phase II as Topic Clinical Trials, Prognosis, Randomized Controlled Trials as Topic, Second Primary Neoplasms, Survival Rate, Vincristine |
| Source: | Leukemia |
| ISSN: | 0887-6924 |
| Publisher: | Nature Publishing Group |
| Volume: | 36 |
| Number: | 2 |
| Page Range: | 580-582 |
| Date: | February 2022 |
| Official Publication: | https://doi.org/10.1038/s41375-021-01386-z |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
